The acute effects of amphetamine derivatives on extracellular serotonin and dopamine levels in rat nucleus accumbens

Pharmacology Biochemistry and Behavior

Volumn 59, Issue 4, 1998, Pages 1003-1009

  Kankaanpää, Aino ^a   Meririnne, Esa ^a   Lillsunde, Pirjo ^a   Seppälä, Timo ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Amphetamine; DOM; Dopamine; MDA; MDMA; Microdialysis; Serotonin (5 HT)

Indexed keywords

AMPHETAMINE DERIVATIVE; DOPAMINE; SEROTONIN;

ANIMAL TISSUE; ARTICLE; DOPAMINE BRAIN LEVEL; DRUG EFFECT; HALLUCINATION; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL;

3,4-DIHYDROXYPHENYLACETIC ACID; AMPHETAMINES; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; EXTRACELLULAR SPACE; HOMOVANILLIC ACID; HYDROXYINDOLEACETIC ACID; MALE; MICRODIALYSIS; NUCLEUS ACCUMBENS; RATS; RATS, WISTAR; SEROTONIN;

ANIMALIA;

EID: 0032052721     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)00527-3     Document Type: Article

References (31)

1. Blaschko H. Amine oxidase and amine metabolism. Pharmacol. Rev. 4:1952;415-458.
2. Carboni E., Imperato A., Perezzani L., Di Chiara G. Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats. Neuroscience. 28:1989;653-661.
3. Fibiger H. C., Phillips A. G. Dopamine and the neural mechanisms of reinforcement. Horn A. S., Korf J., Westerink B. H. C. The neurobiology of dopamine. 1979;597-615 Academic Press, New York.
4. Fuller R. W. Selective inhibition of monoamine oxidase. Adv. Biochem. Psychopharmacol. 5:1972;339-354.
5. Garattini S., Samanin R. The pharmacological profile of some psychomotor stimulant drugs including chemical, neurophysiological, biochemical and toxicological aspects. Hoffmeister F., Stille G. Handbook of experimental pharmacology, vol. 55, Part II. Anxiolytics, gerantopsychopharmacological agents and psychomotor stimulants:1981;545-586 Springer Verlag, Heidelberg.
6. Glennon R. A. Stimulus properties of hallucinogenic phenalkylamines. Formulation of structure-activity relationships NIDA Res. Monogr. Series. 94:1989;43-67.
7. Glennon R. A., Misenheimer B. R. Stimulus effects of N-monoethyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDE) and N-hydroxy-1-(3,4-methylenedioxy-phenyl)-2-aminopropane (N-OH-MDA) in rats trained to discriminate MDMA from saline. Pharmacol. Biochem. Behav. 33:1989;909-912.
8. 2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 35:1984;2505-2511.
9. Glennon R. A. Phenylalkylamine stimulants, hallucinogens, and designer drugs. NIDA Res. Monogr. Series. 105:1991;154-160.
10. 2 antagonists. Eur. J. Pharmacol. 91:1983;189-196.
11. Gough B., Ali S. F., Slikker W. Jr., Holson R. R. Acute effects of 3,4-methylenedioxy-methamphetamine (MDMA) on monoamines in rat caudate. Pharmacol. Biochem. Behav. 39:1991;619-623.
12. Hiramatsu M., Cho A. K. Enantiomeric differences in the effects of 3,4-methylenedioxymethamphetamine on extracellular monoamines and metabolites in the striatum of freely moving rats. An in vivo microdialysis study Neuropharmacology. 29:1990;269-275.
13. 3H]dopamine release from superfused rat brain slices. Eur. J. Pharmacol. 132:1986;269-276.
14. 3H-5-hydroxytryptamine. Pharmacol. Biochem. Behav. 38:1991;505-512.
15. Nash J. F., Nichols D. E. Microdialysis studies on 3,4-methylenedioxyamphetamine and structurally related analogues. Eur. J. Pharmacol. 200:1991;53-58.
16. Nichols D. E., Oberlender R. Structure-activity relationships of MDMA and related compounds. A new class of psychoactive agents? Peroutka S. J. Ecstasy. The clinical, pharmacological and neurotoxicological effects of the drug MDMA:1990;105-131 Kluwer Publishers, Norwell, MA.
17. Nichols D. E. Differences between the mechanisms of action of MDMA, MDBD and the classical hallucinogenis. Identification of a new therapeutic class. Entactogens. J. Psychoact. Drugs 18:1986;305-313.
18. 3H]serotonin from rat brain synaptosomes. J. Med. Chem. 25:1982;530-535.
19. Paxinos G., Watson C. The rat brain in stereotaxic coordinates. 1986;Academic Press, San Diego.
20. Peroutka S. J. Recreational use of MDMA. Peroutka S. J. Ecstasy. The clinical, pharmacological and neurotoxicological effects of the drug MDMA:1990;53-62 Kluwer Publishers, Norwell, MA.
21. Ricaurte G., Bryan G., Strauss L., Seiden L., Schuster C. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science. 229:1985;986-988.
22. Schmidt C. J. Neurotoxicity of the psychedelic amphetamine, methylenedioxy-methamphetamine. J. Pharmacol. Exp. Ther. 240:1987;1-7.
23. Schmidt C. J. Acute administration of methylenedioxymethamphetamine. Comparison with the neurochemical effects of its N-desmethyl and N-ethyl analogs Eur. J. Pharmacol. 136:1987;81-88.
24. Snyder S. H., Faillace L., Hollister L. 2,5-Dimethoxy-4-methyl-amphetamine (STP). A new hallucinogenic drug Science. 158:1967;669-670.
25. 3H] monoamines into synaptosomes from different regions of rat brain. Biochem. Pharmacol. 36:1987;2297-2303.
26. Stone D. M., Stahl D. C., Hanson G. R., Gibb J. W. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur. J. Pharmacol. 128:1986;41-48.
27. Stone D. M., Johnson M., Hanson G. R., Gibb J. W. A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives. Eur. J. Pharmacol. 134:1987;245-248.
28. 2 receptor as a site of acting for LSD and phenylisopropylamine hallucinogens. Psychopharmacology (Berlin). 94:1988;213-216.
29. Wise R. A., Bozarth M. A. Action of drugs of abuse on brain reward systems. An update with specific attention to opiates Pharmacol. Biochem. Behav. 17:1982;239-243.
30. Yamamoto B. K., Spanos L. J. The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur. J. Pharmacol. 148:1988;195-203.
31. Zetterström T., Sharp T., Marsden C. A., Ungerstedt U. In vivo measurement of dopamine and its metabolites by intracerebral dialysis. Changes after D-amphetamine, J Neurochem. 41:1983;1769-1773.